Gastrointestinal Illnesses Archives

Amjevita, a Biosimilar to Humira, Now Available

By

February 2, 2023

Amjevita is supplied as a 40 mg/0.8 mL single-dose prefilled SureClick autoinjector, and as 20 mg/0.4 mL and 40 mg/0.8 mL single-dose prefilled syringes.

Fatty liver, conceptual illustration. Fatty liver is commonly associated with alcohol or metabolic syndrome (diabetes, hypertension and obesity), but can also be due to any one of many causes. Fatty liver disease is a reversible condition wherein large vacuoles of fat (pale yellow circles) accumulate in liver cells.

Gastroenterology Information Center

NPs, PAs Needed to Treat Growing Rates of Liver Disease

By

Kristin Della Volpe

November 10, 2022

Liver disease and cirrhosis now outpace diabetes and stroke as the leading cause of mortality in people aged 25 to 54 years. New survey results shows shortfalls in adoption of national treatment guidelines for liver disease and cirrhosis.

Gastroenterology Information Center

IBD Linked to 9-Fold Increased Risk for Depression

By

Kristin Della Volpe

June 6, 2022

A bidirectional link between inflammatory bowel disease (IBD) and depression was found in a large cohort study; the findings extended to siblings of patients with IBD.

Gastroenterology Information Center

DDW 2022 Updates: IBS, Eosinophilic Esophagitis, and C difficile

By

Kristin Della Volpe

June 6, 2022

Read updates on effective treatments for IBS, the effects of food allergies on proton pump inhibitor efficacy, and oral microbiome therapy for C difficile and more from DDW 2022.

Gastroenterology Information Center

The Effect of Secretor Status on Gut Microbiome Diversity in Acute Gastroenteritis

By

Jessica Nye, PhD

April 18, 2022

Researchers conducted a study to evaluate the relationship between the composition and diversity of the gut microbiome and secretor status among patients with acute gastroenteritis due to norovirus infection.

Gastroenterology Information Center

Novel Microbiome Therapy Reduces Risk for Recurrent C Difficile Infection

By

Emily Pond

March 17, 2022

Investigators assessed the efficacy of a novel microbiome therapeutic, SER-109, for the treatment of recurrent C difficile infection.

Gastroenterology Information Center

Community-Acquired Clostridioides difficile Cases in Children on the Rise

By

Heather Adams, MPAS, PA-C

Elizabeth Nguyen, PA-S

February 23, 2022

An increase in pediatric cases of C difficile is linked to use of broad-spectrum antibiotics, recurrent infections, and a growth in highly virulent strains.